A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Blood (2011) 118 (14): 3765–3776.
Currently there are no citedby results. Try again later.
